Pharmaceutical Pfizer Inc said an oral drug to treat COVID-19 could be available as late as 2021.
Soumyabrata Roy | NurPhoto | Getty Images
pfizer reported first-quarter revenue and adjusted earnings on Tuesday that exceeded Wall Street’s expectations despite a decline in sales due to lower demand for the company’s Covid vaccine.
Here’s what Pfizer reported compared to Wall Street’s expectations, based on a survey of analysts by Refinitiv:
- earnings per share: $1.23 adjusted, versus 98 cents expected
- Income: $18.28 billion, versus the $16.59 billion expected
The pharmaceutical giant posted net income of $5.54 billion, or 97 cents per share. He Compare compared with $7.86 billion, or $1.37 per share, for the same period a year earlier.
The Manhattan, New York-based company maintained its 2023 sales forecast guidance of $67 to $71 billion. Pfizer also reiterated its full-year adjusted earnings outlook for a range of $3.25 to $3.45 per share.
Pfizer will hold an earnings call at 10:00 am ET.
read the earnings release,
This is a developing story. Check back for updates.